About us Quantum Machines (QM) is a company working within the development and commercialization of quantum computing. Established in 2018, QM is the leading provider of qubit-agnostic quantum control and operation systems, providing the world’s cutting-edge researchers and organizations with those critical tools needed to develop useful quantum computers. Quantum Machines is backed by globally recognized venture capital sponsors, including TLV Partners, Battery Ventures, Red Dot Capital Partners, Avigdor Willenz’ investment group, Harel Insurance, and others. In 2022, QM acquired the Danish company QDevil (established in 2016), a developer and producer of electronic instruments and parts specialized for quantum electronics research. Learn more about Quantum Machines here.

BrainCapture is a Danish startup developing a revolutionary medical technology adressing the lack of access to neurological diganostics. This lack of access leads to millions of people going without diagnosis and treatment for conditions like Epilepsy. We believe this significant global issue can be addressed by applying the tools of the 21st century - smartphones, connectivity, AI and automation - to the outdated medical technology and practices currently in use. We also believe that the vast disparity in access to care represents an opportunity. We are creating an Electroencephalogram (EEG) device which is easy to use, telemedicine optimized, and AI assisted in order to offer EEG as a service. The idea of an affordable, portable, connected EEG device has matured rapidly since BrainCapture was founded in 2019. Our founding team consists of leading AI professors from DTU, a Harvard professor in Epilepsy, engineers with execution experience and strong senior investors. We have secured funding through investors and European grants. We are currently expanding the team with several profiles to take us to the next level and deliver a device and technology stack that will change the lives of millions of people all over the world. While our approach to the EEG device is novel, we are not alone. A wave of innovation is sweeping the diagnostics industry. Join us to participate in a once-in-a-generation innovation.

BOXHUB is disrupting the sale of used shipping containers - A global billion-dollar industry. We will make it simple, efficient and transparent for everyone to buy and sell shipping containers By doing this we enable the re-use and upcycling of the 25 million shipping containers currently in circulation around the world. Our customers turn shipping containers into anything from Affordable housing, pop-up restaurants, emergency shelters and a number of sustainable storage solutions.

Noora is a Norwegian climate tech company scaling Nature Based Solutions (NBS) in the Nordics, using technology to quantify the forest’s potential for carbon sequestration and biodiversity improvement, and measure the actual impact for climate and nature. We deliver credible, transparent climate action to organizations ready to take responsibility and create real impact. Our ambition is to scale the impact of Nordic forestry in global climate mitigation. We are now strengthening our commercial team with a committed and experienced Commercial Director to help build and drive Noora’s commercial strategy and hands on work together with the rest of the Noora team.

At Yobr, we see collaboration between students and companies as a way to bring fresh perspectives and the latest skills to real-world challenges. Companies gain flexible, efficient ways to complete meaningful projects that create real value while discovering new talent. For students, it’s an opportunity to apply their skills, learn, and grow in a professional setting. The problem is that most companies struggle to tap into this potential—they don’t have the time, resources, or know-how to make it work. Yobr is changing that. We’re building a platform that leverages AI to simplify project planning, efficiently match yobs with the right students from our talent base, and support execution with intuitive collaboration tools and tailored AI agents. Since starting in January we have done pilots with known brands like SalMar, SpareBank 1 and Norbit, gaining key insight on how students projects should be run. We've developed our technical solution since August, and are looking to launch a beta of our platform in January 2025. We just closed a Angel round and received Innovation Norway's phase 2 grant, targeting break-even and a seed round in Q2 2025. We are a solid team of builders and creators, 3 being full-time and 3 part-time, based in Oslo and Trondheim. Now we are looking to take this to the next level!

Wasted exists to feed people food waste. Coming from the food industry, we’ve seen firsthand how much food is thrown away while people in our communities lack the food they need. We’ve developed the world’s first pasta made from bread waste and a self-sufficient giving model! For each kilogram of pasta we sell, we donate one portion to an organization feeding food-insecure community members.

Gevulot is a generic decentralized prover network designed for deploying arbitrary provers as on-chain programs while maintaining performance similar to centralized provers. The vision of Gevulot is to make the creation of performant zk-based systems, such as validity rollups, as easy as deploying smart contracts.

MinRefusion offers a SaaS solution for automating the process of applying for refunds from the Danish government for employee absence due to sickness, maternity leave, or other reasons. The service is aimed at larger companies that want to save time and resources on manual reporting and avoid errors or missed deadlines. MinRefusion can integrate with various systems such as ERP, accounting, payroll, or time registration, and exchange data with the public platform NemRefusion, which handles the refund applications. MinRefusion secures refunds for both long-term and short-term absences, and provide tools for monitoring reimbursement payments, deadlines, documents, and employee statistics.

We strive for creative ways to make people healthier, think outside the box – and are always curious to learn new things and get things done. So join us in our mission for health and become part of one of Europe's fastest-growing health apps - Stepler! Physical activity has value for the individual, society, and the world. Our mission is to increase movement incentives by gamifying health and rewarding our users' efforts. The outcome? - A healthier lifestyle and a happier wallet :) Do you have what it takes to change our sedentary world once and for all by gamifying health? Then you might fit into our team of talented heroes.

We believe that live esports should be available to everyone, in a way that makes it easy to follow and easy to understand. Our goal is to make it available anytime, anywhere, and to unify it all in one place. That’s why we’re building a platform that will revolutionize the way you consume live esports.

OncoImmunity is a bioinformatics company providing unique machine-learning software to identify tumor-specific mutations that can be targeted by a patient’s own immune system (known as neoantigens). The OncoImmunity solution is important because recent breakthroughs in the field of Immuno-Oncology (I-O) such as the development of checkpoint inhibitors and personalized cancer vaccines, clearly demonstrate that a patient’s immune system can be harnessed to successfully treat cancer. The cost of identifying tumor-specific mutations in a patient’s cancer using next-generation sequencing (NGS) is now trivial and this technology will be key to enabling truly personalized immunotherapies to be developed in a technically and economically feasible manner. However, the remaining challenge that currently limits the field, and which is addressed by the OncoImmunity solution, is predicting which tumor-specific mutations can stimulate a patient’s immune system i.e. are immunogenic. Using NGS data as input, the OncoImmunity software enables accurate patient selection for cancer immunotherapy and can identify optimal targets for personalized cancer vaccines & cell therapies in a clinically actionable time frame. Beginning from this first product offering, OncoImmunity has the vision to become the world’s leading provider of software to guide cancer immunotherapy to improve survival rates for cancer patients. To achieve this OncoImmunity has assembled a growing team of world-class bioinformaticians, data scientists, and software engineers; developing its cutting-edge machine-learning technology that will help fulfill the promise of immunotherapy in the fight against cancer. OncoImmunity’s technology will disrupt the I-O field by offering regulatory-compliant prediction software on a software-as-a-service basis (SaaS). This will allow big pharma, biotechnology, and immunotherapy companies of any size to access OncoImmunity’s cutting-edge prediction software. The company is headquartered in an ideal scientific and entrepreneurial ecosystem to develop its technology at the Oslo Cancer Cluster Incubator; adjacent to the Institute for Cancer Research and the Norwegian Radium Hospital. OncoImmunity is a privately held company, founded in 2014 by experienced bioinformatics scientists (Dr. Trevor Clancy and Professor Eivind Hovig), and an experienced immunologist with a business development background (Dr. Richard Stratford). The company is backed by private financing from the Norwegian Radium Hospital Research Foundation, the Norwegian Cancer Society, STARTUPLAB, and Grotmol Solutions, in addition to a number of private software investors. The company is also supported by grants awarded from the Norwegian Research Council, Innovation Norway, and the EU. The company has already established both national and international collaborations and pilot projects to develop further proof-of-concept data and validate its software.

We provide the banking network, messaging, settlement, and cash management solutions to meet any bank’s requirements. We are based in Fredrikstad, Norway, where UNITE evolved as a correspondent hub for banks, but our origin is global, developed over years in international banking centers. We have studied other initiatives over the years and learned that the third-party philosophy of trying to bolt-on smart software to multiple bank accounts is less than ideal. A holistic revolution was required to deliver a cross-border payments solution fit for banks in the 21st century.

Settle Group (formerly Auka) is a Norwegian fintech company enabling banks to launch their own mobile payments service to fight the competition from third-party providers, startups and other banks. In 2016 we were awarded the fastest-growing fintech company in the EMEA (Europe, Middle East, Africa) by Deloitte. Settle Group has built a white-label financial services platform featuring real-time payments, complex clearing and settlements, card processing and more. Auka is the first regulated financial services company to run fully in the cloud. We first launched our technology to the Norwegian market in 2014 under the brand mCASH. In 2015 we sold the mCASH-operation to SpareBank 1 focusing on global sales of our white-label financial services platform. We’re always on the lookout for skilled personnel sharing our vision to become the backbone of modern banking.

CANNORDIC A/S is a Danish-based MedTech company committed to improving people's lives with products that make a difference. We combine science, nature, and passion to deliver innovative alternatives with high efficacy and bioavailability to patients, especially with autoimmune diseases. We research, develop, manufacture, commercialize and brand over-the-counter (OTC) products under pharmaceutical legislation. Currently, 21 products with cannabidiol aimed at autoimmune and stress-related diseases have been developed. The first 2 products reached Danish stores in 2020, and now 9 products are available on the European market at more than 500 points of sale. Another 12 products will be launched before the end of 2024, with 11 patent-pending products. The product line surpasses competing products on the market by being located at the intersection of natural products, science, and cannabinoid technology while certified under pharmaceutical legislation. To learn more about CANNORDIC and the Cannasen® brand, please visit cannordic.com and cannasen.dk

PROCUREMENT IS COMPLEX – SO WHY MAKE IT HARDER? Our mission is simple and straightforward. We want to rework procurement and B2B payments – and really make it work. By introducing smarter software, we help procurement and finance professionals cut the tail in long-tail procurement. And in turn, cut the expenditure that follows with traditional indirect spend. Mazepay is founded on a belief that the way large enterprises approach indirect procurement can be significantly improved. It is our goal to assist companies in building a sustainable business, where procurement is seen as a business enhancer that drives efficiency, facilitates growth and ensures financial stability. Mazepay is taken to market together with leading European banks and Mastercard. We bring innovative technology to enable seamless B2B payments for indirect purchasing for both buyers and suppliers. Mazepay is headquartered in Aarhus, Denmark with offices in Copenhagen, Denmark and Novi Sad, Serbia. People and culture: Our people and our culture are important to us and what makes working at Mazepay special. We invest in the team and we celebrate our successes together. Outside of work, we have fun through company events such as Friday drinks, dinners, hiking, go-kart, game nights, outdoor trips, etc.